Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man

International Journal of Clinical Pharmacology Research

Volumn 16, Issue 1, 1996, Pages 1-8

  Depre M ^a   Van Hecken, A ^a   Verbesselt, R ^a   Verpooten, G A ^d   Arnout, J ^a   Brunner, F ^b,c   Jurgens, A ^d   Pousset, V ^d   Chow, A ^b,c   Baldauf, C ^b,c   Vermylen, J ^a   De Broe, M ^d   De Schepper, P J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b RW Johnson PRI   (Switzerland)

^c RW Johnson PRI   (United States)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM IONOPHORE; DRUG METABOLITE; LEUKOTRIENE B4; LIPOXYGENASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; TEPOXALIN; THROMBOXANE; THROMBOXANE B2;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; GASTROINTESTINAL DISEASES; HUMANS; LEUKOTRIENE B4; LIPOXYGENASE INHIBITORS; LIVER FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; THROMBOXANE B2;

EID: 8044235832     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Samuelson B. An elucidation of the arachidonic acid cascade discovery of the prostaglandins, thromboxane and leukotrienes. Drugs, 33 2, 1987
2. Davies P., Bailey P.J., Goldenberg M.M., Ford-Hutchinson A.W. The role of arachidonic acid oxygenation products in pain and inflammation. Annu. Rev. Immunol., 2, 335, 1984.
3. Feuerstein G., Hallenbeck J.M. Leukotrienes in health and disease. FASEB J., 1, 186, 1986.
4. Argentieri D.C. et al. Topical and in vitro pharmacology of tepoxalin: a new dual cyclooxygenase (CO)/lipoxygenase (LO) inhibitor. FASEB J., 2, A369, 1988.
5. Capetola R.J. et al. Pulmonary and anti-inflammatory profile of tepoxalin, a dual cyclooxygenase (CO)/lipoxygenase (LO) inhibitor. FASEB J., 2, A369, 1988.
6. Argentieri D.C., Anderson D.W., Ritchie D.M., Rosenthale M.E., Capetola R.J. Tepdxalin (RWJ 20485) inhibits prostaglandin (PG) and leukotriene (LT) production in adjuvant arthritic rats and in dog knee joints challenged with sodium urate and immune complexes. FASEB J., 4, A1142, 1990.
7. Wallace J. et al. Comparison of the ulcerogenic properties of tepoxalin with those of non-steroidal anti-inflammatory drugs (NSAIDs). Agents Actions, 34, 247, 1991.
8. Hoet B. et al. R68070, a combined thromboxane-endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin. Blood, 75, 646, 1990.
9. Diamant Z. et al. The effect of MK-0591 a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J. Allergy Clin. Immunol., 95, 43, 1995.
10. Ritchie D.M., Argentieri D.C., Lau C., Barbone A.G. Cytokine modulation by lepoxalin - a dual cyclooxygenase (CO)/lipoxygenase (LO) inhibitor with potential antirheumatic activity. Proceedings World Congr. Inflammation, Vienna. Abstract P141 (1993).
11. kB dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase. J. Cell. Biochem., 57, 299, 1995.